Precision medicine pioneer to establish new clinical lab in Arizona, bringing predictive testing for renal denervation to market

SCOTTSDALE, Ariz., Oct. 21, 2026 /PRNewswire/ — Xcellerant Ventures today announced a $1 million Fund I investment in Geneticure, a precision medicine pioneer developing tests that predict patient response to hypertension treatments. The capital will accelerate Geneticure’s commercial scaling and support a new clinical laboratory in Arizona, expanding the state’s thriving life sciences ecosystem.

Geneticure utilizes a non-invasive cheek swab test to analyze four physiologic pathways, predicting whether a patient with resistant hypertension will respond to renal denervation (RDN)—an FDA-approved procedure with 35 million eligible U.S. patients. Because more than 10 million of those patients may see no benefit, Geneticure’s responder score gives physicians confidence in patient selection, lowers payer costs, and drives clinical adoption.

“Renal denervation is a game-changer, but identifying the right candidates has been the critical missing link,” said Mike Shufeldt, General Partner at Xcellerant Ventures. “Geneticure delivers that clarity. We are thrilled to back a team with deep Arizona roots as they build a state-of-the-art laboratory here, bringing healthtech innovation and biotech jobs to our local economy.”

“Increasing our presence in Arizona puts Geneticure close to the clinical partners and talent we need to scale,” said Scott Snyder, CEO of Geneticure. “Xcellerant brings more than capital, and we are excited to work with their team as we bring renal denervation responder testing to physicians and patients.”

Geneticure will use the funding to advance clinical validation, refine its reimbursement strategy, and build commercial readiness ahead of a planned Series A round. Alongside its RDN platform, Geneticure holds four U.S. patents and offers a commercial hypertension test guiding daily medication selection.

While Xcellerant’s institutional Fund I is now closed, individual investors can access Xcellerant’s early-stage healthcare pipeline through Jetstream Venture Fund (jvf.vc), a first-of-its-kind, retail-accessible venture fund designed to democratize VC investing.

About Geneticure

Geneticure is a precision medicine company with operations in Arizona and Minnesota. Its patented genetic tests help physicians predict patient response to hypertension treatments, including medication selection and renal denervation. geneticure.com.

About Xcellerant Ventures

Xcellerant Ventures is a Scottsdale, Arizona-based venture capital firm investing in early-stage healthcare technology companies that improve clinical outcomes and reduce costs. xcellerantventures.com. 

Media Contact: Dawson Fearnow, dawson@mmprmarketing.com, 602-264-2655

View original content:https://www.prnewswire.com/news-releases/xcellerant-ventures-invests-1m-in-geneticure-to-advance-precision-medicine-and-expand-arizonas-biotech-hub-302912338.html

SOURCE Xcellerant Ventures